Clinical trials: sponsored by M.D. Anderson Cancer Center
Glioblastoma, Gliosarcoma
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or…
- Trial name
- NCT04555577
- Testing
- Peposertib, Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
- Trial name
- NCT06284564
- Testing
- Evolocumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
- Trial name
- NCT05287451
- Testing
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Liver
Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.
- Trial name
- NCT05879159
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Dysplasia, Lip and Oral Cavity Carcinoma
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders.
- Conditions
- Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder, Premalignant Lesion
- Trial name
- NCT02790853
- Testing
- Biopsy, Fluorescence Imaging, High-Resolution Microendoscopy
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to…
- Trial name
- NCT04810091
- Testing
- Questionnaire Administration, Telotristat Ethyl
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Liver Neoplasm
Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study
This phase II trial studies how well software-aided imaging works in confirming tumor coverage with ablation (the removal or destruction of a body part or tissue or its function) on patients with liver tumors.
- Trial name
- NCT04083378
- Testing
- Ablation Therapy, Image-Guided Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Caregiver, Patient
Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose
This trial studies the attitudes and beliefs of high risk patients and caregivers regarding the prescription of intranasal naloxone spray for opioid overdose.
- Trial name
- NCT04129138
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs.
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer
- Trial name
- NCT01590069
- Testing
- Aerosolized Aldesleukin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Evaluating, Intermittent Fasting
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic…
- Conditions
- Evaluating, Intermittent Fasting, Pancreatic Cancer
- Trial name
- NCT07513116
- Testing
- intermittent fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Localized Skin Lesion, Mycosis Fungoides
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
This phase II trial studies how well ultra low dose radiation therapy works in treating patients with mycosis fungoides. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
- Trial name
- NCT03398161
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
- Trial name
- NCT07318389
- Testing
- SOC (Standard of care), Bevacizumab, Cetuximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Thyroid Cancer
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination.
- Trial name
- NCT07470489
- Testing
- Cemiplimab, Zanzalintinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Selumetinib and Olaparib in Solid Tumors
This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given…
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs
- Trial name
- NCT03162627
- Testing
- Selumetinib, Olaparib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Leukemia
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
The goal of Phase 1b is to establish the safety of asciminib in combination with FLAG-Ida and venetoclax in patients with CML-MBP, CML-LBP, and Ph+ AML.
- Trial name
- NCT07604233
- Testing
- Fludarabine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Gliomas
Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas
The goal of this clinical research study is to learn about the safety and effects of G207 combined with radiation therapy in patients with recurrent or progressive high-grade glioma (HGG).
- Trial name
- NCT07649070
- Testing
- G207
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
To learn if cemiplimab can help to control dMMR colon cancer.
- Trial name
- NCT05961709
- Testing
- Cemiplimab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Non-Small Cell Lung Cancer
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.
- Trial name
- NCT07415005
- Testing
- Lorlatinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Survivorship, Meal Kit
Food Is Medicine In Survivorship (Foodiis-AYA): Examining The Feasibility And Acceptability Of A Remotely-Delivered Meal Kit And Culinary Medicine Program For Survivors Of Adolescent/Young Adult (AYA) Cancer
To study the feasibility of a new nutritional intervention (Food is Medicine in Survivorship - Adolescents / Young Adults [FoodiiSAYA]) for patients 18-25 years old who have completed cancer treatment.
- Conditions
- Survivorship, Meal Kit, Culinary Medicine
- Trial name
- NCT07871773
- Testing
- Meal Preps, Questionnaire
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Survivor, Dysphagia
Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors
This trial studies how well manual therapy works in treating fibrosis-related late effect dysphagia in head and neck cancer survivors.
- Conditions
- Cancer Survivor, Dysphagia, Fibrosis, Head and Neck Carcinoma
- Trial name
- MANTLE (NCT03612531)
- Testing
- Manual Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center